Healthcare / BiotechnologyTaipei Exchange
$17.45
+0.35 (+2.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-144.2M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-109.8%
↓Gross Margin
16.6%
↓Debt/Equity
1.15
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.5%
FCF CAGR
—
FCF margin
-305.9%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $48.2M · net income $-164.3M · FCF $-147.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $48.2M | $48.2M | $39.9M | $43.5M | $188.4M |
| Net Income | $-164.3M | $-164.3M | $-157.5M | $-223.7M | $-248.0M |
| EBITDA | $-151.5M | $-151.5M | $-155.8M | $-229.0M | $-258.4M |
| EPS | — | — | -2.20 | -3.40 | -3.87 |
| Gross Margin | 16.6% | 16.6% | 35.6% | -53.7% | 11.1% |
| Operating Margin | -387.6% | -387.6% | -379.0% | -559.4% | -149.4% |
| Net Margin | -341.0% | -341.0% | -394.7% | -514.4% | -131.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.15 | 1.15 | 0.29 | 0.14 | 0.05 |
| Current Ratio | 1.16 | 1.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-147.4M | $-147.4M | $-144.2M | $-138.1M | $-201.0M |
| Returns | |||||
| ROE | -109.8% | -109.8% | -42.1% | -69.5% | -45.5% |
| Valuation | |||||
| P/B | 8.41 | 8.41 | 4.89 | 7.56 | 7.26 |
| Growth & Yield | |||||
| Revenue Growth | 20.7% | 20.7% | -8.2% | -76.9% | — |
| EPS Growth | — | — | 35.3% | 12.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.20 → n/d
Residual
-0.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.